The global Human cytomegalovirus 65 kDa Phosphoprotein market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Human cytomegalovirus 65 kDa Phosphoprotein volume and value at global level, regional level and company level. From a global perspective, this report represents overall Human cytomegalovirus 65 kDa Phosphoprotein market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Human cytomegalovirus 65 kDa Phosphoprotein in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Human cytomegalovirus 65 kDa Phosphoprotein manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Astellas Pharma Inc
Hookipa Biotech AG
Immunomic Therapeutics Inc
Vakzine Projekt Management GmbH
Vaximm AG
VBI Vaccines Inc
Vical Inc
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
HB-101
CyMVectin
ASP-0113
PepVax
Others

Segment by Application
Brain Tumor
Hemotaological Tumor
Kidney Transplant Rejection
Liver Transplant Rejection
Others